In conjunction with: Research to Prevent Blindness Alliance for Aging Research Association for Research in Vision and Ophthalmology European Vision Institute Lighthouse Guild Macula Vision Research Foundation Continues education about eye and vision research with a Briefing that begins the Third Annual Emerging Vision Scientists Day on Capitol Hill held [...]
Video of Dr. Temple on the Dr. Oz Show On Tuesday, February 14, 2017, NSCI’s Scientific Director and MVRF-funded researcher, Dr. Sally Temple was a guest on the Dr.Oz Show: Dr. Temple was asked to participate on the show as a stem cell expert and the current President of the International Society for Stem Cell [...]
Named for Friedrich Best, who characterized the disease in 1905, Best disease, also known as vitelliform macular dystrophy, affects children and young adults and can cause severe declines in central vision as patients age. The disease is one in a group of conditions known as bestrophinopathies, all linked to mutations in the BEST1 gene. This [...]
(CNN) As we grow older, a common disease called macular degeneration can threaten our eyesight. An experimental stem cell treatment proved effective at halting this disease with no serious side effects up to a year later, a study published Wednesday in the New England Journal of Medicine found. It is the first treatment using personalized, genetically [...]
The Macula Vision Research Foundation (MVRF) and VisionCare, Inc. have formed a unique partnership of industry and philanthropy to benefit more than 15 million people in the United States with age-related macular degeneration (AMD). The goal of this partnership is to increase awareness of potential treatments for AMD including the CentraSight treatment program, which includes [...]
An international team from the University of Alabama at Birmingham and University College London and Queens University Belfast in the United Kingdom developed a cell culture model that could help to develop earlier treatment strategies for age-related macular degeneration, the third most prevalent cause of vision loss worldwide. In AMD, which is twice as prevalent [...]
Many readers have been following closely the development of Squalamine Eye Drops for wet age-related macular degeneration, hoping that a self-administered at-home eye drop could reduce, or even eliminate, the need for monthly or as-needed eye injections. Unfortunately, a clinical trial designed to test this concept has produced disappointing results: Squalamine Eye Drops failed to [...]
Lucentis prefilled syringe offers a ready-to-use option to deliver treatment with fewer steps First anti-VEGF prefilled syringe FDA-approved to treat people with wet age-related macular degeneration and people with macular edema after retinal vein occlusion SOUTH SAN FRANCISCO, Calif. – October 14, 2016 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: [...]
Curing blindness is a big deal! Check out National Geographic's Cover Story September 2016 Issue featuring important information on AMD that the world needs to know more about. We are even more optimistic! Link to article: http://www.nationalgeographic.com/magazine/2016/09/blindness-treatment-medical-science-cures/
MVRF is Proud to Co-Sponsor the Second Annual Emerging Vision Scientists Day on Capitol Hill On September 14, 2016, we will be co-hosting a special Congressional Briefing entitled, Advances in the Diagnosis and Treatment of Age-Related Macular Degeneration (AMD) and Retinal Diseases presented by Amir H. Kashani, MD, PhD (USC Gayle and Edward Roski Eye Institute/Keck School [...]
